MYL News and Press, Mylan N.V. From 05/12/20

HERTFORDSHIRE, England and PITTSBURGH , May 12, 2020 /PRNewswire/ --  Mylan N.V.  (NASDAQ: MYL) today announced, as part of its ongoing efforts to support patients and public health needs during the COVID-19 pandemic, a global collaboration with Gilead Sciences to expand acces...

Gilead Sciences ( GILD -1.2% ) has out-licensed non-exclusive rights to antiviral remdesivir to India's Jubilant Life Sciences allowing the latter to sell the drug in 127 countries including India. More news on: Gilead Sciences, Inc., Mylan N.V., Healthcare stocks news, Read more ....

Mylan N.V. (MYL) Q1 2020 Earnings Call Transcript May 11, 2020 10:30 am ET Company Participants Melissa Trombetta - Head of Global Investor Relations Robert J. Coury - Chairman & Non-Executive Director Heather M. Bresch - Chief Executive Officer & Executive Director Raj...

Image source: The Motley Fool. Mylan N.V.   (NASDAQ: MYL) Q1 2020 Earnings Call May 11, 2020 , 10:30 a.m. ET Operator Continue reading

You might say that  Mylan (NASDAQ: MYL) is a company in waiting. At some point over the next few months, its merger with Pfizer 's Upjohn will close. Mylan will be no more; a new company named Viatris will be created from the merger. In the meantime, investors no longer have to wait to...

The following slide deck was published by Mylan N.V. in conjunction with their 2020 Q1 earnings Read more ...

Mylan ( MYL ) Q1 results : More news on: Mylan N.V., Healthcare stocks news, Earnings news and commentary, , Read more ...

HERTFORDSHIRE, England and PITTSBURGH , May 11, 2020 /PRNewswire/ --  Mylan N.V. (NASDAQ: MYL) today announced its financial results for the three months ended March 31, 2020 and reaffirmed its financial guidance for the full year. First Quarter 2020 Financial Highligh...

Mylan (NASDAQ: MYL ) is scheduled to announce Q1 earnings results on Monday, May 11th, before market open. The consensus EPS Estimate is $0.87 (+6.1% Y/Y) and the consensus Revenue Estimate is $2.65B (+6.0% Y/Y). Over the last 2 years, MYL has beaten EPS estimates 63% of the time and...

A dividend cut is on the way for one of the biggest drugmakers in the world. But it's not because of the COVID-19 pandemic. It's not because of financial problems at all. Pfizer (NYSE: PFE) will lower its dividend payout at some point later this year for a straightforward reason. The pharma...